Skinny shots on TikTok: what GLP-1 videos get wrong

What's this video probably claiming?

Based on the caption and hashtag set, this video is almost certainly pitching GLP-1 receptor agonists, likely semaglutide or tirzepatide, under the breezy label "skinny shots." The hashtag combination of fatdissolving and bodysculpting suggests the creator may be conflating two entirely different categories of injectable treatments: GLP-1 medications (which are systemic prescription drugs that affect appetite and metabolism) and fat-dissolving injectables like deoxycholic acid. These are not the same thing, and blurring them matters clinically. The call-to-action language, "Order your skinny shots today," implies easy, low-friction access, which raises real questions about whether a prescriber is involved or whether this is routing viewers toward compounding pharmacies operating in regulatory gray zones. The loveyourself branding wraps a medical product in wellness language designed to lower skepticism.

What does the science actually show?

The actual clinical data on GLP-1 receptor agonists is genuinely strong, which is part of why the hype is so hard to push back against. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg weekly produced mean weight loss of 14.9% of body weight over 68 weeks in adults with obesity, compared to 2.4% with placebo. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide at the 15 mg dose produced up to 20.9% mean weight loss at 72 weeks. These are real, peer-reviewed numbers from large randomized controlled trials. What those trials do not show is that the medication works as a cosmetic sculpting tool, or that it selectively removes fat from specific body areas. Weight loss is systemic. The gastrointestinal side effect profile, including nausea in up to 44% of participants in STEP 1, also tends to disappear from the TikTok version of the story.

Where does the social media noise diverge from clinical reality?

The gap between TikTok's "skinny shots" framing and clinical reality is wide on several fronts. First, the fatdissolving hashtag is doing real damage here. Deoxycholic acid injections (brand name Kybella) are FDA-approved only for submental fat, require precise anatomical placement by trained providers, and carry risks including nerve injury and tissue necrosis if misapplied. GLP-1 agonists do not dissolve fat locally at all. Mixing these concepts in a single content bucket misleads viewers about mechanism, safety profile, and what they are actually ordering. Second, compounded semaglutide, which is what many low-cost "order now" telehealth funnels actually dispense, is not FDA-approved and is not therapeutically equivalent to Wegovy or Ozempic. The FDA issued warnings about compounded semaglutide products in 2024 specifically because of dosing errors and contamination risks. Third, "order today" framing skips over the clinical evaluation that legitimate prescribing requires.

What should you actually know?

GLP-1 receptor agonists are legitimate, well-studied medications for obesity and type 2 diabetes management. They are not cosmetic injectables, they are not fat-dissolving agents, and they are not over-the-counter products. They require a prescriber who has reviewed your medical history, current medications, and contraindications, including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, which are listed as contraindications in the Ozempic and Wegovy prescribing information. The SCALE trial for liraglutide (Pi-Sunyer et al., 2015, NEJM) and the STEP and SURMOUNT programs confirm meaningful clinical benefit in appropriate candidates, but "appropriate" is doing a lot of work in that sentence. Weight regain after discontinuation is also substantial: Wilding et al. (2022, Diabetes, Obesity and Metabolism) found two-thirds of weight lost during STEP 1 was regained within a year of stopping semaglutide. Anyone selling you a "skinny shot" without a conversation about long-term management is selling you an incomplete picture.